Blacksmith Medicines

About:

Blacksmith Medicines developing medicines targeting metal-dependent enzymes found in human physiology.

Website: https://blacksmithmedicines.com/

Top Investors: Eli Lilly, Alexandria Venture Investments, Evotec, National Institute of Allergy and Infectious Diseases, MP Healthcare Venture Management

Description:

Blacksmith Medicines developing medicines targeting metal-dependent enzymes found in human physiology. Over 30% of known enzymes are metalloenzymes, covering all major enzyme classes: oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. Metal ions, including magnesium, zinc, iron, manganese and copper, are the essential ingredient in these metalloenzymes.

Total Funding Amount:

$3.3M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Diego, California, United States

Founded Date:

2017-01-01

Contact Email:

amy(AT)juniper-point.com

Founders:

Zachary Zimmerman

Number of Employees:

11-50

Last Funding Date:

2024-02-21

IPO Status:

Private

Industries:

© 2025 bioDAO.ai